Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The CPRX news feed on Stock Titan aggregates company announcements, financial updates, scientific disclosures, and investor conference appearances drawn from Catalyst’s own public communications and regulatory filings.
Readers can find earnings and financial result announcements, where Catalyst reports product revenue contributions from FIRDAPSE, AGAMREE, and FYCOMPA, along with commentary on operating performance and business outlook. These releases often discuss factors such as organic growth in Lambert-Eaton myasthenic syndrome markets, demand in Duchenne muscular dystrophy centers of excellence, and the impact of generic competition on specific products.
The news stream also features corporate and strategic updates, including authorization of share repurchase programs, patent litigation settlements related to FIRDAPSE, and developments in clinical practice guidelines that reference conditions and therapies linked to the company’s portfolio. In addition, Catalyst regularly announces participation in major healthcare and investor conferences, providing insight into how management presents the story behind CPRX to the investment community.
For those following the scientific and patient-focused side of the business, the news includes conference presentations and advocacy initiatives, such as real-world analyses in Duchenne muscular dystrophy, research on Lambert-Eaton myasthenic syndrome, and programs like the Catalyst Advocacy Scholars Summit with academic partners. Investors, analysts, and patients can use this page to monitor how Catalyst’s rare disease strategy, clinical activities, and capital allocation decisions evolve over time. Bookmark this CPRX news page for a centralized view of the company’s key public announcements.
Catalyst Pharmaceuticals (CPRX) will release its third quarter 2022 financial results on November 9, 2022, after market close. A subsequent conference call and webcast will occur on November 10, 2022, at 8:30 AM ET, where the management team will discuss the results and provide a corporate update. FIRDAPSE®, approved in 2018, is available for treating adults and children with Lambert-Eaton myasthenic syndrome in the U.S. and Canada. Forward-looking statements highlight potential risks that may affect results significantly.
Catalyst Pharmaceuticals (Nasdaq: CPRX) has announced FDA approval for FIRDAPSE® (amifampridine) to treat Lambert-Eaton myasthenic syndrome (LEMS) in patients aged six years and older. This expands the treatment option for pediatric patients, addressing a significant need within a small patient population. FIRDAPSE was previously approved for adults in the U.S. and Canada. The company is committed to ensuring access through its Catalyst Pathways program, which provides support for qualifying patients.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Chairman and CEO, and the management team will attend the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. An on-demand presentation will be accessible to registered attendees on September 12 at 7:00 AM Eastern Time via the conference portal. Additionally, the presentation will be available on Catalyst's website. The company specializes in developing novel medicines for rare diseases, notably with FDA-approved FIRDAPSE® for Lambert-Eaton myasthenic syndrome.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced its participation in Citi's 17th Annual BioPharma Conference on September 7-8, 2022. Chairman and CEO Patrick J. McEnany, along with the management team, will host one-on-one meetings on September 8. Catalyst is dedicated to developing and commercializing innovative medicines for rare diseases, including its recently FDA-approved drug FIRDAPSE® for Lambert-Eaton myasthenic syndrome.
FIRDAPSE is also approved for use in Canada, showcasing Catalyst's commitment to addressing unmet medical needs in rare diseases.
Catalyst Pharmaceuticals (CPRX) reported record Q2 2022 net product revenues of $53.0 million, marking a 57.7% year-over-year increase. Cash and short-term investments totaled $220.8 million with no funded debt. The company completed the acquisition of Ruzurgi® U.S. and Mexico rights, potentially extending FIRDAPSE patent protection to 2037. Catalyst forecasts full-year adjusted EBITDA between $100-105 million and expects total revenues between $195-205 million, reflecting a 38%-45% increase from 2021.
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release its Q2 2022 financial results after market close on August 9, 2022. A conference call and webcast are scheduled for August 10, 2022, at 8:30 AM ET, where management will discuss the results and provide a corporate update. The event can be accessed via the company's website, and a replay will be available for 30 days. Catalyst focuses on developing medicines for rare diseases, with its FDA-approved product FIRDAPSE® for Lambert-Eaton myasthenic syndrome.
Catalyst Pharmaceuticals announced a settlement with Jacobus Pharmaceutical, acquiring rights to Ruzurgi in the U.S. and Mexico. This settlement resolves patent infringement litigation where Catalyst claimed Jacobus induced infringement related to FIRDAPSE. Notably, Ruzurgi is not FDA-approved for U.S. distribution due to legal complications. Catalyst plans to continue supplying Ruzurgi to patients under investigator-sponsored INDs while focusing on the LEMS patient community. Catalyst will pay Jacobus cash and a royalty on U.S. net sales of amifampridine.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced participation in two upcoming investment conferences. CEO Patrick J. McEnany and the management team will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 4 PM ET, and the Jefferies Healthcare Conference on June 8, 2022, at 11 AM ET. A webcast will be available on their website, with a replay for 14 days. Catalyst focuses on developing treatments for rare diseases and has FDA-approved FIRDAPSE for Lambert-Eaton myasthenic syndrome.
Catalyst Pharmaceuticals (CPRX) reported record revenue of $43.1 million for Q1 2022, marking a 42.7% year-over-year increase. This growth is attributed to increased patient conversions to FIRDAPSE® after Ruzurgi® was removed from the U.S. market. The company affirmed its full-year revenue guidance of $195 million to $205 million, expecting a 38% to 45% revenue growth from 2021. Catalyst's cash position stands at $198 million with no debt. It continues to enhance its patent portfolio and expand treatment options for rare diseases.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced it will release its first-quarter 2022 financial results on May 10, 2022, after market close. A conference call and webcast will be hosted the next morning, May 11, 2022, at 8:30 AM ET, to discuss financial results and provide corporate updates. Catalyst focuses on developing medicines for patients with rare diseases, with its FIRDAPSE® medication approved for Lambert-Eaton myasthenic syndrome. Further details and a replay of the webcast will be available on the company's website.